Literature DB >> 26693654

[The early clinical efficacy of allogeneic corneal lens inlays in correction of hyperopia].

Yuehua Zhou1, Jing Zhang2, Yan Zheng2, Qian Liu2, Wenbin Wei2, Ningli Wang2.   

Abstract

OBJECTIVE: To evaluate the safety, effectiveness and predictability of allogeneic corneal lens inlays in correcting hyperopia.
METHODS: In this case series study. Twenty-one hyperopic patients (37 eyes) received allogeneic corneal lens inlays. The range of preoperative spherical equivalent was 3.25 to 10.00 D, and the mean value was (6.84 ± 2.79)D. All the cases were followed up for 3 months. Uncorrected and best corrected visual acuity and refraction were compared before and after operation. Corneal topography and optical coherence tomography were performed. Ocular response analyzer was used to evaluate the shifts of corneal hysteresis.
RESULTS: No intraoperative or postoperative complications were found. Uncorrected distance and near visual acuities (UCDVA and UCNVA) were improved obviously after surgery UCDVA was improved from (4.64 ± 0.25) to (4.89 ± 0.14) (F = 5.919, P < 0.001), and UCNVA was improved from J4.94 to J1.18 (F = 4.926, P < 0.01). The UCNVA in 31 eyes (83.8%) was J1 at 3 months after surgery. Mild overcorrection was the state early after operation, and the refractive power was stable at 1 month after surgery. The average residual spherical equivalent was (-0.63 ± 0.94)D, which was improved significantly from (6.84 ± 2.79)D before surgery. There was no obvious hyperopic regression. The corneal biomechanics did not change before and after surgery.
CONCLUSIONS: Allogeneic corneal lens inlays can be used to correct hyperopic eyes with good safety, effectiveness and predictability. It provides a new choice for hyperopic patients.

Entities:  

Mesh:

Year:  2015        PMID: 26693654

Source DB:  PubMed          Journal:  Zhonghua Yan Ke Za Zhi        ISSN: 0412-4081


  1 in total

1.  Comparison of clinical outcome of small-incision lenticule intrastromal keratoplasty and FS-LASIK for correction of moderate and high hyperopia.

Authors:  Li Zhang; Yue-Hua Zhou; Chang-Bin Zhai; Jing Zhang; Yan Zheng
Journal:  Int J Ophthalmol       Date:  2022-05-18       Impact factor: 1.645

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.